Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis ...

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis ...

Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor…

Oculis SA Receives FDA Agreement on Phase 3 Trial Design for Optic Neuritis Drug OCS-01

Oculis SA announced an agreement with the U.S. Food and […] The post Oculis SA Receives FDA Agreement on Phase 3 Trial Design for Optic Neuritis Drug OCS-01 first appeared on GeneOnline News. The post Oculis SA Receives FDA Agreement on Phase 3 Trial Design for Optic Neuritis Drug OCS-01 appeared first on GeneOnline News.